Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

37P - Interleukin-1β effect on the efficacy of cytostatic drugs in vitro


16 Sep 2021


ePoster Display


Tumour Immunology;  Cancer Biology;  Pathology/Molecular Biology

Tumour Site


Anna Malkova


Annals of Oncology (2021) 32 (suppl_5): S361-S375. 10.1016/annonc/annonc684


A. Malkova1, R. Orlova1, A. Gubal2, K. Semenov3, V. Sharoyko2

Author affiliations

  • 1 Medicine, Saint-Petersburg State university, 199106 - Saint-Petersburg/RU
  • 2 Chemistry, Saint-Petersburg State university, 199106 - Saint-Petersburg/RU
  • 3 Chemistry, Pavlov First Saint Petersburg State Medical University, Saint Petersburg/RU


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 37P


Interleukin-1β (IL-1β) is an inflammatory cytokine; however, in the tumor microenvironment it exhibits pro-oncogenic properties, inducing angiogenesis, metastasis, and local immunosuppression. In this regard, various approaches to the use of IL-1β inhibitors in cancer patients are being considered. However, such treatment should be based on knowledge of cytokine expression in tumor tissue and local immune status.


For the experiments we used a human alveolar basal epithelial adenocarcinoma cell line (A549) incubated in a full culture medium DMEM (Paneco, Russia) supplemented with 10 mM HEPES-Na, 2 mM glutamine, 10% fetal bovine serum and 1% penicillin, streptomycin, IL-1β solution, and cytostatic drug solution. After 24 hours of incubation IL-1β was added to the cells with a final concentration of 1 ng/ml in the well. After 24 hours, a cytostatic drug was added to some of the cells, the final concentration in the well was 50 μM. The control line were A549 cells without additional treatment. After 24 hours MTT assay was performed to assess the total cellular metabolic activity as an indicator of viability, proliferation and cytotoxicity. The study was carried out with the support of RFBR grants 20-015-00498 and 21-515-10007.


Under the influence of IL-1β the degree of mitochondrial activity in lung cancer cells decreased relative to the control by 34.73%, when exposed to a cytostatic drug - by 42.99%, in the presence of IL-1β and a cytostatic drug - by 45.05%.


According to the MTT test the presence of IL-1β contributed to a decrease in mitochondrial activity in tumor cells, which was enhanced by the action of a cytostatic agent. Possibly, IL-1β of 1 ng/ml with a short incubation time has an antitumor effect, which enhances the efficacy of cytostatics. The results obtained might confirm the importance of the timely initiation of chemotherapy, when pro-inflammatory processes prevail in the tumor microenvironment, and a personalized approach when choosing additional treatment methods.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


RFBR grants 20-015-00498 and 21-515-10007.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.